Lupus nephritis (LN) is a pathologically heterogenous autoimmune disease linked to end-
stage kidney disease and mortality. Better therapeutic strategies are needed as only 30 …

The KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
represents the first update to this set of recommendations since the initial set of KDIGO …

Kidney involvement in patients with lupus highly increases morbidity and mortality. In recent
years, several reports have emphasized the dissociation between clinical and histological …

Abstract Background Leveraging the Accelerating Medicines Partnership (AMP) Lupus
Nephritis (LN) dataset, we evaluated longitudinal patterns, rates, and predictors of response …

Objectives Reportedly, patients with LN and low-level proteinuria have favourable short-term
renal outcomes. We aimed to clarify the long-term renal outcomes and overall survival of …

Objective To estimate real-life European Alliance of Associations for Rheumatology
(EULAR)/European Renal Association (ERA)-European Dialysis and Transplantation …

Background: In a phase 3 study of adults with active lupus nephritis, addition of voclosporin
to mycophenolate mofetil (MMF) and low-dose glucocorticoids led to significant …

Introduction Current rheumatology and nephrology society guidelines in lupus nephritis do
not recommend renal biopsy for proteinuria of less than 500 mg/24 h. This might lead to a …

Objective Lupus nephritis (LN) can occur as an isolated component of disease activity or be
accompanied by diverse extrarenal manifestations. Whether isolated renal disease is …

Objectives Proteinuria is a marker of lupus nephritis (LN) activity and damage. We aimed to
explore the impact of baseline proteinuria level on long-term outcomes. Methods We …